68Ga-NODAGA-LM3与68Ga-DOTA-LM3在前瞻性随机双盲研究中的安全性、生物分布与剂量学比较
两种示踪剂耐受性良好,68Ga-DOTA-LM3在多个正常器官的摄取显著低于68Ga-NODAGA-LM3,两者均显示良好的肿瘤摄取与滞留,有效剂量相近。
要点
- 两种SSTR2拮抗剂示踪剂均耐受良好,仅68Ga-DOTA-LM3组2例出现恶心、1例呕吐。
- 68Ga-DOTA-LM3在垂体、腮腺、肝、脾、胰、肾上腺、胃、小肠和肾的摄取显著低于68Ga-NODAGA-LM3。
- 两种示踪剂有效剂量相近,膀胱壁为吸收剂量最高的器官。
核心结论
- 68Ga-NODAGA-LM3与68Ga-DOTA-LM3均具有良好的生物分布、高肿瘤摄取和良好肿瘤滞留,图像对比度高。
- 两种示踪剂的剂量学数据与其他68Ga标记SSTR2拮抗剂相当。
研究设计与样本
- 评估正常器官生物分布、肿瘤摄取和安全性,采用OLINDA/EXM(版本1.0)计算辐射剂量学。
主要发现
- 其余14例患者的PET图像进一步分析,68Ga-DOTA-LM3在垂体、腮腺、肝、脾、胰、肾上腺、胃、小肠和肾的器官摄取显著低于68Ga-NODAGA-LM3。
- 共分析38个病灶(68Ga-NODAGA-LM3组18个,68Ga-DOTA-LM3组20个),两种示踪剂均显示良好肿瘤摄取和滞留。
- 68Ga-NODAGA-LM3组肿瘤病灶SUVmax从5分钟的平均31.3 ± 19.7增至2小时的74.6 ± 56.3,增幅138%。
- 68Ga-DOTA-LM3组注射后5分钟肿瘤摄取即达高水平,平均SUVmax为36.6 ± 23.6,至注射后30分钟继续增至45.3 ± 29.3。
关键数值与推荐
- 68Ga-NODAGA-LM3平均有效剂量为0.026 ± 0.003 mSv/MBq,68Ga-DOTA-LM3为0.025 ± 0.002 mSv/MBq。
- 两组中膀胱壁均为吸收剂量最高的器官。
临床怎么用
- 两种68Ga标记SSTR2拮抗剂均可用于分化良好的神经内分泌肿瘤PET/CT显像,具有高图像对比度。
- 68Ga-DOTA-LM3正常器官摄取较低,可能有利于降低背景、改善病灶检出。
局限性
- 作者指出需进一步研究68Ga-NODAGA-LM3和68Ga-DOTA-LM3的潜在拮抗效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-NODAGA-LM3 (where LM3 is p-Cl-Phe-cyclo(d-Cys-Tyr-d-4-amino-Phe(carbamoyl)-Lys-Thr-Cys)d-Tyr-NH2) and 68Ga-DOTA-LM3 are somatostatin receptor subtype 2 (SSTR2)-specific antagonists used for PET/CT imaging. The purpose of this study was to evaluate the safety, biodistribution, and dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors. Methods: Patients were equally randomized into 2 arms, with arm A receiving 68Ga-NODAGA-LM3 and arm B receiving 68Ga-DOTA-LM3. Serial PET scans were acquired at 5, 15, 30, 45, 60, and 120 min after 68Ga-NODAGA-LM3 (200 MBq ± 11 MBq/40 μg of total peptide mass) or 68Ga-DOTA-LM3 (172 MBq ± 21 MBq/40 μg of total peptide mass) injection. The biodistribution in normal organs, tumor uptake, and safety were assessed. Radiation dosimetry was calculated using OLINDA/EXM (version 1.0). Results: Sixteen patients, 8 in each arm, were recruited in the study. Both tracers were well tolerated in most patients. Two patients in arm B had nausea (grade 2), and one of them had vomiting (grade 1). The PET images of the other 14 patients were further analyzed. Significantly lower organ uptake was observed in the pituitary, parotids, liver, spleen, pancreas, adrenal, stomach, small intestine, and kidneys with 68Ga-DOTA-LM3 than with 68Ga-NODAGA-LM3. In total, 38 lesions were analyzed, including 18 with 68Ga-NODAGA-LM3 and 20 with 68Ga-DOTA-LM3. Both tracers showed good tumor uptake and retention. With 68Ga-NODAGA-LM3, the tracer accumulation in tumor lesions increased by 138%, from an average SUVmax of 31.3 ± 19.7 at 5 min to 74.6 ± 56.3 at 2 h. With 68Ga-DOTA-LM3, the tumor uptake rapidly reached a high level at 5 min after injection, with an average SUVmax of 36.6 ± 23.6, and continued to increase to 45.3 ± 29.3 until 30 min after injection. The urinary bladder wall was the organ receiving the highest absorbed dose in both arms. The mean effective dose was 0.026 ± 0.003 mSv/MBq for 68Ga-NODAGA-LM3 and 0.025 ± 0.002 mSv/MBq for 68Ga-DOTA-LM3. Conclusion: Both 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 show favorable biodistribution, high tumor uptake, and good tumor retention, resulting in high image contrast. The dosimetric data are comparable to those for other 68Ga-labeled SSTR2 antagonists. Further studies are required to look into the potential antagonistic effects of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3.
引用
- Zhu W, Cheng Y, Jia R, et al. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021. PMID: 33579804. doi:10.2967/jnumed.120.253096
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。